Next Post

Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update

[ad_1] Vaxcyte, Inc. — Company Continues to Advance Phase 2 Portion of the Ongoing Phase 1/2 Clinical Proof-of-Concept Study Evaluating VAX-24 in Adults Aged 18 to 64 for the Prevention of Invasive Pneumococcal Disease and Pneumonia — — Announcement of Topline Safety, Tolerability and Immunogenicity Results from Both the Phase […]

You May Like